Products Categories
CAS No.: | 100286-90-6 |
---|---|
Name: | Irinotecan hydrochloride |
Article Data: | 24 |
Molecular Structure: | |
Formula: | C33H38N4O6.HCl |
Molecular Weight: | 623.149 |
Synonyms: | [1,4'-Bipiperidine]-1'-carboxylicacid,(4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride(9CI);[1,4'-Bipiperidine]-1'-carboxylic acid,4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride,(S)-;1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline, [1,4'-bipiperidine]-1'-carboxylic acid deriv.;7-Ethyl-10-[[4-(1-piperidyl)-1-piperidyl]carbonyloxy]camptothecin hydrochloride;CPT 11;Campto;Camptosar;Camptothecin 11;Camptothecin 11 hydrochloride;Topotecin;U 101440E; |
EINECS: | 600-054-0 |
Melting Point: | 250-256 ºC (dec.) |
Boiling Point: | 873.4 ºC at 760 mmHg |
Flash Point: | 482 ºC |
Solubility: | Soluble in DMSO at 100mg/ml. Soluble in water at 25mg/ml with warming |
Appearance: | Yellow crystalline powder |
Hazard Symbols: | Xn |
Risk Codes: | 22 |
PSA: | 114.20000 |
LogP: | 4.76890 |
irinotecan
irinotecan hydrochloirde
Conditions | Yield |
---|---|
With hydrogenchloride In dichloromethane; water at 0℃; for 2 - 3h; Product distribution / selectivity; | 100% |
With hydrogenchloride In tetrahydrofuran; water Product distribution / selectivity; | 100% |
With hydrogenchloride In water Product distribution / selectivity; | 95% |
4-piperidinopiperidin
7-ethyl-10-hydroxycamptothecin
irinotecan hydrochloirde
Conditions | Yield |
---|---|
Stage #1: 4-piperidinopiperidine-1-carbonyl chloride hydrochloride; 7-ethyl-10-hydroxycamptothecin With triethylamine In pyridine; dichloromethane at 30 - 40℃; for 1.5h; Stage #2: 4-piperidinopiperidin In pyridine; dichloromethane for 0.5h; | 90% |
7-ethyl-10-hydroxycamptothecin
irinotecan hydrochloirde
Conditions | Yield |
---|---|
Stage #1: 4-piperidinopiperidine-1-carbonyl chloride hydrochloride; 7-ethyl-10-hydroxycamptothecin With pyridine; triethylamine In dichloromethane at 30 - 40℃; for 1.5h; Stage #2: With 4-piperidinopiperidin In dichloromethane at 0 - 80℃; for 0.5h; pH=4.0; Stage #3: With hydrogenchloride In water; acetonitrile at 20℃; for 20h; Product distribution / selectivity; | 90% |
Stage #1: 4-piperidinopiperidine-1-carbonyl chloride hydrochloride; 7-ethyl-10-hydroxycamptothecin With pyridine; triethylamine In dichloromethane at 20℃; for 2h; Stage #2: With hydrogenchloride In water at 0 - 80℃; for 20h; pH=4.0; Product distribution / selectivity; | 80% |
With triethylamine In pyridine; dichloromethane; water at 20℃; for 2h; | 80% |
irinotecan hydrochloirde
Conditions | Yield |
---|---|
With Britton-Robinson's buffer pH 6.0; water at 37℃; Equilibrium constant; Kinetics; Thermodynamic data; Ea, A, var. pH, var. temp., var. time; |
irinotecan hydrochloirde
Conditions | Yield |
---|---|
With hydrogenchloride In ethanol; n-heptane; water at 0 - 10℃; for 1h; pH=< 4; | |
With hydrogenchloride In ethanol; water; ethyl acetate at 0 - 10℃; for 1h; pH=< 4; | |
With hydrogenchloride In ethanol; water; ethyl acetate at 0 - 10℃; for 1h; pH=< 4; | |
With hydrogenchloride In methanol; water; ethyl acetate at 0 - 10℃; for 1h; pH=< 4; | |
With hydrogenchloride In methanol at 50℃; |
irinotecan hydrochloirde
Conditions | Yield |
---|---|
With hydrogenchloride In methanol; water at 50℃; |
4-piperidinopiperidin
irinotecan hydrochloirde
Conditions | Yield |
---|---|
Multi-step reaction with 3 steps 1.1: dichloromethane; acetonitrile / 20 - 70 °C 1.2: 20 °C 2.1: triethylamine; pyridine; acetamide / dichloromethane / 2 h / 30 - 40 °C / Inert atmosphere 3.1: hydrogenchloride / water View Scheme | |
Multi-step reaction with 3 steps 1.1: dichloromethane; hexane; acetonitrile / 20 - 25 °C 1.2: 20 °C 2.1: pyridine / dichloromethane; acetamide / 2 h / 30 - 40 °C / Inert atmosphere 3.1: hydrogenchloride / water / 20 h / 2 - 70 °C View Scheme | |
Multi-step reaction with 3 steps 1: dichloromethane / 0 - 20 °C 2: 1-Methylpyrrolidine / dichloromethane / 20 - 45 °C 3: hydrogenchloride / water / 3 h / 70 °C View Scheme | |
Multi-step reaction with 3 steps 1: N,N-dimethyl-formamide / 3 h / 60 - 65 °C 2: dichloromethane / 6 h / 45 - 50 °C 3: hydrogenchloride / water / 12 h / 20 °C View Scheme |
7-ethyl-10-hydroxycamptothecin
irinotecan hydrochloirde
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: triethylamine; pyridine; acetamide / dichloromethane / 2 h / 30 - 40 °C / Inert atmosphere 2: hydrogenchloride / water View Scheme | |
Multi-step reaction with 2 steps 1: pyridine / dichloromethane; acetamide / 2 h / 30 - 40 °C / Inert atmosphere 2: hydrogenchloride / water / 20 h / 2 - 70 °C View Scheme |
4-piperidinopiperidine-1-carbonyl chloride
irinotecan hydrochloirde
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: triethylamine; pyridine; acetamide / dichloromethane / 2 h / 30 - 40 °C / Inert atmosphere 2: hydrogenchloride / water View Scheme | |
Multi-step reaction with 2 steps 1: pyridine / dichloromethane; acetamide / 2 h / 30 - 40 °C / Inert atmosphere 2: hydrogenchloride / water / 20 h / 2 - 70 °C View Scheme |
(4S)-4-ethyl-7,8-dihydro-4-hydroxy-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione
irinotecan hydrochloirde
Conditions | Yield |
---|---|
Multi-step reaction with 3 steps 1: trifluoroacetic acid / toluene / 20 h / 85 - 90 °C / Industry scale 2: 1-Methylpyrrolidine / dichloromethane / 20 - 45 °C 3: hydrogenchloride / water / 3 h / 70 °C View Scheme |
What can I do for you?
Get Best Price
In 2004, a clinical study was performed that both validated prospectively the association of the variant with greater toxicity and the ability of genetic testing in predicting that toxicity before chemotherapy administration.
In 2005, the FDA made changes to the labelling of irinotecan to add pharmacogenomics recommendations that patients with polymorphisms in UGT1A1 gene, specifically the variant, should perhaps receive reduced drug doses. Irinotecan is one of the first widely-used chemotherapy agents that is dosed for each patient according to his genotype.
1. Introduction of Irinotecan hydrochloride
Irinotecan hydrochloride is yellow crystalline powder or white or off-white crystalline powder. Its systematic name is called (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 1,4'-bipiperidine-1'-carboxylate hydrochloride (1:1). Irinotecan hydrochloride belongs to product categories of Active Pharmaceutical Ingredients; Antineoplastic; Antitumors for Research and Experimental Use; Biochemistry; Chiral Reagents; Inhibitors; Intermediates & Fine Chemicals; Pharmaceuticals; Irinotecan.
This chemical is a yellow crystalline powder and should be sealed in a cool, dry place at the temperature of 2-8 °C. Besides, its Classification Code is Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Drug / Therapeutic Agent; Enzyme Inhibitors; Mutation data; Radiation-Sensitizing Agents; Reproductive Effect; Topoisomerase I Inhibitors; Topoisomerase Inhibitors. Irinotecan hydrochloride Solubility is DMSO (50 mg/ml).
2. Properties of Irinotecan hydrochloride
Physical properties about Irinotecan hydrochloride are:
(1)ACD/LogP: 4.18; (2)# of Rule of 5 Violations: 2; (3)ACD/LogD (pH 5.5): 1.09; (4)ACD/LogD (pH 7.4): 2.53; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 19.89; (7)ACD/KOC (pH 5.5): 3.63; (8)ACD/KOC (pH 7.4): 100.73; (9)#H bond acceptors: 10; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 6; (12)Polar Surface Area: 101.51 Å2; (13)Flash Point: 482 °C; (14)Enthalpy of Vaporization: 132.98 kJ/mol; (15)Boiling Point: 873.4 °C at 760 mmHg; (16)Vapour Pressure: 1.31E-32 mmHg at 25 °C.
3. Structure Descriptors of Irinotecan hydrochloride
You can still convert the following datas into molecular structure:
(1) SMILES: Cl.O=C7OCC=6C(=O)N2C(\c1nc5c(c(c1C2)CC)cc(OC(=O)N4CCC(N3CCCCC3)CC4)cc5)=C/C=6[C@@]7(O)CC
(2) InChI: InChI=1S/C33H38N4O6.ClH/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1H/t33-;/m0./s1
(3) InChIKey: GURKHSYORGJETM-WAQYZQTGSA-N
4. Toxicity of Irinotecan hydrochloride
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | intravenous | 40mg/kg (40mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING | Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 7185, 1990. |
mouse | LD50 | intraperitoneal | 177mg/kg (177mg/kg) | Cancer Research. Vol. 47, Pg. 5944, 1987. | |
mouse | LD50 | intravenous | 132mg/kg (132mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 7185, 1990. |
mouse | LD50 | oral | 765mg/kg (765mg/kg) | Cancer Research. Vol. 47, Pg. 5944, 1987. | |
rat | LD50 | intravenous | 83600ug/kg (83.6mg/kg) | Cancer Research. Vol. 47, Pg. 5944, 1987. | |
rat | LD50 | oral | 867mg/kg (867mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 7185, 1990. |
6. Uses of Irinotecan hydrochloride
Irinotecan hydrochloride is a DNA topoisomerase inhibitor. What's more, Irinotecan hydrochloride is used as DNA topoisomerase inhibitor and antineoplastic. It can inhibitor of DNA topoisomerase I that displays antitumor activity against a range of tumor types.